TY - JOUR
T1 - Global Variation in Magnetic Resonance Imaging Quality of the Prostate
AU - the PRIME Quality Improvement Group
AU - Giganti, Francesco
AU - Ng, Alexander
AU - Asif, Aqua
AU - Wai-Shun Chan, Vinson
AU - Rossiter, Marimo
AU - Nathan, Arjun
AU - Khetrapal, Pramit
AU - Dickinson, Louise
AU - Punwani, Shonit
AU - Brew-Graves, Chris
AU - Freeman, Alex
AU - Emberton, Mark
AU - Moore, Caroline M.
AU - Allen, Clare
AU - Kasivisvanathan, Veeru
AU - Dias, Adriano Basso
AU - Haider, Aiman
AU - Khan, Amara
AU - Tong, Angela
AU - Rannikko, Antti
AU - Kenttämies, Anu
AU - Rastinehad, Ardeshir R.
AU - Stabile, Armando
AU - Villers, Arnauld
AU - Tewari, Ash
AU - Oto, Aytekin
AU - Israël, Bas
AU - Gaing, Byron
AU - Cho, Carmen Chi Min
AU - González, Carolina Aulló
AU - Lee, Chau Hung
AU - Wetterauer, Christian
AU - Kesch, Claudia
AU - Adamo, Daniel A.
AU - Margolis, Daniel J.A.
AU - López Ruiz, Daniel José
AU - Margel, David
AU - Murphy, Declan
AU - Gómez, Enrique Gómez
AU - Chun, Felix
AU - Preisser, Felix
AU - Thomas, Francis
AU - Villeirs, Geert
AU - Marra, Giancarlo
AU - Giannarini, Gianluca
AU - Brembilla, Giorgio
AU - Robert, Grégoire
AU - Manenti, Guglielmo
AU - Cash, Hannes
AU - Potyka, Ingrid
N1 - Publisher Copyright:
© 2023 Radiological Society of North America Inc.. All rights reserved.
PY - 2023/10
Y1 - 2023/10
N2 - Background: High variability in prostate MRI quality might reduce accuracy in prostate cancer detection. Purpose: To prospectively evaluate the quality of MRI scanners taking part in the quality control phase of the global PRIME (Prostate Imaging Using MRI ± Contrast Enhancement) trial using the Prostate Imaging Quality (PI-QUAL) standardized scoring system, give recommendations on how to improve the MRI protocols, and establish whether MRI quality could be improved by these recommendations. Materials and Methods: In the prospective clinical trial (PRIME), for each scanner, centers performing prostate MRI submitted five consecutive studies and the MRI protocols (phase I). Submitted data were evaluated in consensus by two expert genitourinary radiologists using the PI-QUAL scoring system that evaluates MRI diagnostic quality using five points (1 and 2 = nondiagnostic; 3 = sufficient; 4 = adequate, 5 = optimal) between September 2021 and August 2022. Feedback was provided for scanners not achieving a PI-QUAL 5 score, and centers were invited to resubmit new imaging data using the modified protocol (phase II). Descriptive comparison of outcomes was made between the MRI scanners, feedback provided, and overall PI-QUAL scores. Results: In phase I, 41 centers from 18 countries submitted a total of 355 multiparametric MRI studies from 71 scanners, with nine (13%) scanners achieving a PI-QUAL score of 3, 39 (55%) achieving a score of 4, and 23 (32%) achieving a score of 5. Of the 48 (n = 71 [68%]) scanners that received feedback to improve, the dynamic contrast-enhanced sequences were those that least adhered to the Prostate Imaging Reporting and Data System, version 2.1, criteria (44 of 48 [92%]), followed by diffusion-weighted imaging (20 of 48 [42%]) and T2-weighted imaging (19 of 48 [40%]). In phase II, 36 centers from 17 countries resubmitted revised studies, resulting in a total of 62 (n = 64 [97%]) scanners with a final PI-QUAL score of 5. Conclusion: Substantial variation in global prostate MRI acquisition parameters as a measure of quality was observed, particularly with DCE sequences. Basic evaluation and modifications to MRI protocols using PI-QUAL can lead to substantial improvements in quality.
AB - Background: High variability in prostate MRI quality might reduce accuracy in prostate cancer detection. Purpose: To prospectively evaluate the quality of MRI scanners taking part in the quality control phase of the global PRIME (Prostate Imaging Using MRI ± Contrast Enhancement) trial using the Prostate Imaging Quality (PI-QUAL) standardized scoring system, give recommendations on how to improve the MRI protocols, and establish whether MRI quality could be improved by these recommendations. Materials and Methods: In the prospective clinical trial (PRIME), for each scanner, centers performing prostate MRI submitted five consecutive studies and the MRI protocols (phase I). Submitted data were evaluated in consensus by two expert genitourinary radiologists using the PI-QUAL scoring system that evaluates MRI diagnostic quality using five points (1 and 2 = nondiagnostic; 3 = sufficient; 4 = adequate, 5 = optimal) between September 2021 and August 2022. Feedback was provided for scanners not achieving a PI-QUAL 5 score, and centers were invited to resubmit new imaging data using the modified protocol (phase II). Descriptive comparison of outcomes was made between the MRI scanners, feedback provided, and overall PI-QUAL scores. Results: In phase I, 41 centers from 18 countries submitted a total of 355 multiparametric MRI studies from 71 scanners, with nine (13%) scanners achieving a PI-QUAL score of 3, 39 (55%) achieving a score of 4, and 23 (32%) achieving a score of 5. Of the 48 (n = 71 [68%]) scanners that received feedback to improve, the dynamic contrast-enhanced sequences were those that least adhered to the Prostate Imaging Reporting and Data System, version 2.1, criteria (44 of 48 [92%]), followed by diffusion-weighted imaging (20 of 48 [42%]) and T2-weighted imaging (19 of 48 [40%]). In phase II, 36 centers from 17 countries resubmitted revised studies, resulting in a total of 62 (n = 64 [97%]) scanners with a final PI-QUAL score of 5. Conclusion: Substantial variation in global prostate MRI acquisition parameters as a measure of quality was observed, particularly with DCE sequences. Basic evaluation and modifications to MRI protocols using PI-QUAL can lead to substantial improvements in quality.
UR - http://www.scopus.com/inward/record.url?scp=85173316015&partnerID=8YFLogxK
U2 - 10.1148/radiol.231130
DO - 10.1148/radiol.231130
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???
C2 - 37815448
AN - SCOPUS:85173316015
SN - 0033-8419
VL - 309
JO - Radiology
JF - Radiology
IS - 1
M1 - e231130
ER -
